GlassScriptPhysician profile
Irwin G Linton
NPI 1154371649
$3,915.51
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $1,092 · 2021: $1,369 · 2022: $565.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $394.16 | 2019-2022 | |
| Amgen INC. | $324.92 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $290.03 | 2019-2021 | |
| Abbvie INC. | $248.51 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $220.29 | 2019-2021 | |
| Allergan, INC. | $207.60 | 2019-2020 | |
| Novo Nordisk INC | $207.29 | 2019-2022 | |
| Astellas Pharma US INC | $206.46 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.27 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $172.20 | 2019-2022 | |
| Pfizer INC. | $127.29 | 2019-2021 | |
| Lilly USA, LLC | $125.29 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $112.03 | 2020 | |
| Glaxosmithkline, LLC. | $104.94 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $100.38 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $92.09 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $89.39 | 2019-2020 | |
| Mylan Specialty L.P. | $84.81 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $82.66 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $71.48 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.75 | 2019-2021 | |
| Assertio Therapeutics, INC. | $54.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.61 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $40.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.61 | 2021 | |
| Almatica Pharma LLC | $34.54 | 2021 | |
| Nabriva Therapeutics, Plc | $31.93 | 2021 | |
| Redhill Biopharma INC. | $22.89 | 2021 | |
| Radius Health, INC. | $21.37 | 2021 | |
| Antares Pharma, INC. | $19.64 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.29 | 2021 | |
| Strongbridge US INC. | $17.11 | 2020 | |
| Esperion Therapeutics, INC. | $16.68 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.73 | 2019 | |
| Eisai INC. | $13.68 | 2021 | |
| Biogen, INC. | $12.34 | 2021 | |
| Biodelivery Sciences International, INC. | $11.37 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irwin Linton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.